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Abstract: Objectives: Most non-melanoma skin tumors are treated with conventional methods, being the most common 
surgery. However, satisfactory surgical treatment can be very challenging for patients with large or multiple lesions. In 
cases where the tumor is located on the face, hands or genital areas, the results may be suboptimal in terms of 
aesthetics and/or function. A high dose-rate brachytherapy using non-sealed Rhenium-188 was developed to offer a 
personalized solution for these cases as well as cases where a surgical approach was not preferred. Here we show a 
retrospective analysis of 43 patients treated with this technique. 
Methods: The technique, called dermatological high-dose-rate beta-brachytherapy (DBBR), is a brachytherapy based on 
a non-sealed beta-emitter embedded in a complex specially-designed acrylic matrix. We use Rhenium-188 as the beta-
emitter. This matrix is applied over the tumor, which is protected by a special thin plastic foil avoiding any direct physical 
contact of the radioisotope with the skin. After the calculated required amount of time, the protective foil with the applied 
radioactive acrylic matrix is removed. 43 patients (basal/squamous cell carcinomas, BCCs and SCCs) were treated with 
this technique after histological confirmation of the non-melanoma skin tumor. Patients were then followed up, to 
evaluate wound healing as well as potential side-effects and recurrences. 
Results: 29 BCC and 14 SCC patients were treated with DBBR. 36/42 achieved complete clinical remission with only 1 
application (24 BCC, 12 SCC) and 6/42 with 2 applications (4 BCC, 2 SCC); 1 BCC patient was lost to follow-up before 
wound closing. In 4 of the 6 patients (3 BCC, 1 SCC) treated twice the second treatment was planned due to the 
thickness of the tumor; in the remaining 2 patients (1 BCC, 1 SCC) the second treatment was needed to treat a 
recurrence at the border of the previously treated area. No side effects were reported. Wound healing was complete in 
34-180 days (average 65 days, median 53) for all 42 patients that were followed-up. An average follow-up of 288 days 
(after one or two treatments) showed no single recurrence (42 patients). 
Conclusions: DBBR is a very promising alternative for treatment of BCCs and SCCs for all cases in which a surgical 
approach is not recommended or accepted by the patient. 
Keywords: NMSC (Non-melanoma skin cancer), BCC (Basal cell carcinoma), SCC (Squamous cell carcinoma), 
Brachytherapy, Rhenium-188. 
INTRODUCTION 
Brachytherapy has been used to treat skin tumors 
since the early 1900s [1]. As an alternative to electron 
beam device which have a large footprint and deposit a 
significant dose beyond the dermis due to secondary 
radiation, skin brachytherapy resulted to be a great 
option [2]. Among others, Iridium-192 is the isotope 
mostly used due to its long half-life (73.8 days) and its 
emission profile that includes beta (539-675 keV) and 
gamma radiation (296-612 keV). This combination 
made it possible to obtain high-doses in the epidermis 
without damaging underlying layers. Depending on the  
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radioactivity and the isotope used, brachytherapy with 
sealed sources is classified as low (0.4-2 Gy/h), 
medium (2-12 Gy/h) or high-dose-rate (>12 Gy/h), the 
high-dose-rate being the most commonly used [3]. 
Iridium-192, Radium-226, Cesium-131, Iodine-125, 
Paladium-103 or other brachytherapy sources are 
sealed and commonly placed on the tip of a wire which 
can be introduced in so-called applicators. An 
applicator is usually bell-shaped and made of lead or 
tungsten. During the treatment, this applicator is placed 
over the skin tumor and the radioactive wire is 
introduced through a small aperture, such that it can 
irradiate the skin from a few millimeters distance during 
a controlled time, while the patient and the medical 
personnel are not exposed. Applicators can have 
different sizes, such that different tumor areas can be 
treated [4]. 
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This however poses a practical problem as tumors 
rarely are planar or have a regular shape. If the lesion 
to be treated is located in areas with complex geometry 
such as ears, lips or genitals, the placement of the 
applicator is cumbersome and dosimetry calculations 
can become very complicated. They are commonly 
oversimplified in the planning software [5]. 
In 2005, Sedda et al. proposed the use of a non-
sealed radioactive matrix which could be applied over 
the tumor [6]. The idea was to bring the radionuclide as 
close to the tumor as possible, being independent of its 
three-dimensional shape. Sedda et al also introduced 
Rhenium-188 as the isotope which brought further 
advantages: Rhenium-188 emits stronger beta 
radiation (1.9-2.1 MeV) than Iridium-192, while its 
gamma component is in the range of gamma imaging 
(150 keV). As a result the dose distribution in the skin 
is less steep than for Iridium-192, but also drops to 
almost zero within the first millimeters [7]. 
These non-invasive approaches present significant 
benefits for non-melanoma skin cancer patients where 
the conventional surgical approach can be problematic 
or simply is not desired. This is the case of elderly 
people, where co-morbidities make surgery cumber- 
some or even contraindicated because it could result in 
negative side effects [8]. Also patients with large or 
multiple lesions are candidates for alternative 
therapies, since surgery could result in complicated 
interventions with multiple steps and sometimes 
including skin transplantation [9]. Finally with increasing 
patient awareness, patients with lesions on the face, 
the hands or the genitals may opt for non-surgical 
treatments in the hope of reducing the likelihood of 
unsatisfying aesthetic results or the loss of function 
[10]. 
MATERIALS AND METHODS 
Our method for high-dose-rate brachytherapy 
prefers Rhenium-188 due to the following arguments. 
a) Beta-emissions: With an energy spectrum in the 
range of 1.9-2.1 MeV, Rhenium-188’s beta 
particles penetrate human tissue up to 1cm. 
However, 92% of the doses are deposited within 
the first 3 mm. Compared to Iridium-192, the 
dose distribution is less steep and has a lighter 
tail (Figure 1). 
b) Gamma-emissions: The main gamma 
component (15% of emissions) has energy of 
150keV. This does not contribute significantly to 
the therapeutic aspect nor to the radiation 
burden to the patient and the users. Its presence 
makes it however easier to detect contamination, 
using conventional gamma detectors. Since  
150 keV gamma photons can be detectedby 
conventional SPECT cameras, the latter could 
be used for therapy monitoring. This advantage 
plays a major role when comparing Rhenium-
188 with Yttrium-90, which has a similar beta-
emission profile (2.3 MeV) but no significant 
gamma nor X-ray component. 
c) Half-life: If the irradiation is meant to be 
personalized and a non-sealed source is used, 
the half-life should be selected to be short to 
minimize the risk of incorporation and simplify 
logistics. This is different than in brachytherapy 
that is not personalized and uses sealed sources 
that should rather live long to minimize costs. 
With 17.0 h, Rhenium-188 is an excellent choice 
if compared to Yttrium-90 with 64.0 hours. As an 
example the amount of Rhenium-188 needed for 
treating an average patient can be disposed 
within 2-3 weeks, while the similar amount of 
Yttrium-90 would need 8-9 weeks. 
d) Production: If personalized treatment is needed, 
the isotopes should be flexibly obtained. 
Rhenium-188 is commonly obtained from W-
188/Re-188 generators. Likewise Y-90 can be 
obtained from Sr-90/Y-90 generators. In such a 
setup the decision in favor of Rhenium-188 is 
taken based on considerations about potential 
break-through of the mother isotopes and the 
impact of a potential incorporation as well as 
waste management. As it is well known from the 
data arising from the Techa river cohort, 
Stronium-90 is incorporated in the bones and 
has impact on the health of contaminated 
persons down to their offspring [11, 12]. With a 
half-life of 28.8 years Strontium-90 poses a 
bigger risk than Tungsten-188 with a half-life of 
only 69.4 days. Furthermore, Tungsten-188 is 
expected to have a major uptake only in the 
thyroid and a rather fast wash-out, as seen in 
experiments with mice [13]. On the side of waste 
management, a potential break-through of 1ppm 
would require storage of 272 days for Tungsten-
188, but 112.6 years for Strontium-90. 
In the initial work of Sedda et al, the radioactive 
material was applied directly over the tumor with only a 
thin layer of transparent petroleum jelly cream. This 
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layer was meant to minimize the risk of incorporation of 
the radioactive matrix through the skin or wounds. The 
highly insoluble dirhenium-heptasulfide was selected to 
avoid diffusion of the radionuclide through the matrix 
and later the jelly, but also its evaporation. Dirhenium-
heptasulfide which forms microscopic particles  
(Figure 2) can be obtained from perrhenate, the eluate 
of the W-188/Re-188 generators. 
In order to further minimize the risk of incorporation, 
we introduced a sterile transparent surgical foil that 
covers the skin and makes it even harder for the 
radioactive particles to reach the skin. Several surgical 
foils were tested in terms of permeability as well as 
mechanical resistance to the dirhenium-heptasulfide 
and the components of the acrylic matrix. Additionally, 
the mechanical resistance of the foil was tested after 
irradiation with 100 Gy, which is above the planned 
use. “Aerofilm”, manufactured by Aero Healthcare 
(UK), was selected as it fulfilled all pre-requisites and 
passed all tests. 
The need for a sterile foil comes from the fact that 
sometimes skin tumors are ulcerated. Also, debulking 
the tumor may be useful by means of curettage or 
surgery in cases where it grew over the normal surface 
of the skin. 
The next modification was to the application. A tool 
was designed to hold the radioactive matrix and apply it 
with a brush, while keeping it properly shielded with 
tungsten. In order to allow the operator to see the area 
being treated and at the same time protect his/her 
hand, a 10mm thick transparent PMMA glass was ad- 
ded to the tool. 10mm of PMMA essentially blocks the 
beta-emissions of Rhenium-188 completely (Figure 3). 
The complex specially-designed acrylic resin matrix 
and the Rhenium-188 in form of insoluble dirhenium-
 
Figure 1: Right, dose at different skin depth for Rhenium-188 versus Iridium-192 for a comparable total dose of 65 Gy within the 
first 1.5mm. Simulations were performed using NRC’s VARSKIN 5.2 software [14]. Left, schematics of simulated scenarios with 
VARSKIN. 
 
Figure 2: Left, particle size distribution of dirhenium-heptasulfide from our production. Right, scanning electron microscope 
image of dirhenium-heptasulfide particles (round). 
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heptasulfide microparticles are contained in a single 
use sealed and calibrated “carpoule”, that is loaded into 
the application hand held tool. 
For dosimetry calculations a set of tables was 
generated for different target depths (300, 400, 500, 
600, 700 µm…) using the simulation software by the 
U.S. Nuclear Regulatory Commission (VARSKIN 5.2 
[14]). The software was validated using measurements 
both in phantom setups and in patients [15]. Exemplary 
measured patient dose curves can be found in [6]. The 
overall concept is to determine the time needed for a 
(lethal) dose of 50 Gy to be delivered at a given depth. 
At the skin surface the dose rate is commonly >100 
mSv/h. In terms of radiation dose for the rest of the 
body due to the gamma component, we calculated in 
the worst case scenario 0.85 mSv/GBq/h. 
The result of the improvements is a simple 10 step 
procedure: 
1. Delineation of the tumor border including a 
safety margin of 3-5 mm on the skin of the 
patient with a dermatological pen. The safety 
margin was selected to match the common 
margin used in surgery. 
2. Determination of the area to be treated, in cm2. 
3. Covering of lesion(s) with the protective foil. 
4. If treating area is near the eyes, covering of the 
eyes with lead protections. This step is of major 
importance to avoid damage of the eye lenses, 
in particular since up to 90% of all non-
melanoma skin cancers are located on the face. 
5. Loading of a carpoule into the application tool 
and measurement of the initial radioactivity. 
6. Application of the radioactive ready-to-use matrix 
over the foil along marked area using the 
application tool. 
7. Measurement of the remaining radioactivity in 
the carpoule in theapplication tool. 
8. Calculation of treatment time based on the 
difference of initial and remaining radioactivity, 
the determined area to be treated and the target 
depth. 
      
       
Figure 3: Top left, tool for application of radioactive matrix on patient during a procedure. Bottom left, table used for calculation 
of treatment time for a given target depth (here a protocol of 50 Gy to 300 µm). Right, physician fully equipped with radiation 
protection clothes. 
118    International Journal of Nuclear Medicine Research, 2017 Cipriani et al. 
9. Removal of the foil with the radioactive matrix 
after the end of the treatment time. 
10. Control of contamination. 
Following the analysis of the database of the S. 
Eugenio Hospital, in Rome, we found 43 patients with 
87 lesions who had a complete histological record, 
dosimetry information and imaging material suiting the 
evaluation in this work. The group consisted of 18 
females and 25 males. 
Lesions were located all over the body (Figure 4). 4 
patients had multiple lesions. All lesions were 
confirmed by histology. Where needed, epilumine- 
scence images where taken. 
The method described above was used to treat the 
patients. If a scab was present it was removed before 
application of the foil. For this step the scab was first 
softened for several minutes with a saline solution. In 
case of multiple lesions, each lesion was treated 
separately. 
For genitals and lips, a skin dose of 50 Gy was 
applied at 300 µm since mucous tissue is more 
sensitive to radiation; here the rationale is to do a 
fractioning in 2-3 treatments with 6-12 months between 
fractions. For relapses the irradiation depth of 50 Gy 
was set to 600 µm. For all other anatomies or 
situations the target dose was 50 Gy to 500 µm. BCC 
and SCC were treated equally. 
Follow-up took place without a particular regime. In 
case a recurrence of the therapy was detected during 
follow-up a second treatment was considered. 
 
Figure 4: Distribution of lesion localization within the 43 patients. 
 
Table 1: Distribution of Histology and Reason for DBBR given Anatomy. *Patient Lost to Follow-up had a Tumor on 
the Cheek. #Patient Lost to Follow-up was Treated due to Advanced Age 
 Histology Reason for DBBR 
 BCC SCC Age Recurrence Localization Multiple 
Scalp 24 0 1 0 0 23 
Forehead 2 0 0 1 0 1 
Temple 1 0 1 0 0 0 
Nose 14 1 9 5 0 1 
Ear 2 1 0 0 3 0 
Cheek 7* 3 6# 3 0 1 
Lip 1 1 0 0 2 0 
Neck 5 0 0 0 0 5 
Back 5 0 0 0 0 5 
Penis 0 4 0 0 4 0 
Arm 5 0 0 0 0 5 
Hand 0 1 0 1 0 0 
Leg 8 3 3 0 0 8 
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RESULTS 
29 basal cell carcinoma (BCC) patients and 14 
squamous cell carcinoma (SCC) patients were treated. 
One of the SCC patients had an in situ tumor (Bowen’s 
disease). One of the BCC patients had a pigmented 
BCC, 4 of them were ulcerated, 1 was nodular and 1 
was sclerodermiform. In all patients a surgery was not 
indicated due to anatomical localization (9), age (18), 
and multiple tumors (4) or as surgery had previously 
failed (11). Among the 11 patients that were 
unsuccessfully treated with surgery prior to therapy, 1 
of them had one, 2 of them three interventions. Among 
the 4 patients that had multiple lesions, 1 of them had 
23 lesions on the scalp, 1 had 20 lesions on arms, legs, 
neck, back and the forehead. Multiple lesions were 
treated in a single session regardless of the number of 
them. 
Treatment times varied from 15 minutes to 2 hours, 
in average 61 minutes and median 59 minutes  
(Figure 5). The dose-rate was in average 57.8 Gy/h 
(median 50.8 Gy/h). The treatment area varied 
between 1 cm2 and 49 cm2 (single lesion), in average 
the area treated was 5 cm2 with a median of 3 cm2 
(Figure 5). Application was painless in all cases. No 
single side-effect or adverse event was reported during 
treatment. Contamination was not found in any of the 
cases confirming the impermeability of the foil. In 2 
cases due to a tumor thickness > 500µm or in 2 cases 
due to anatomical location (ear and penis), the 
treatment was planned to be performed in 2 steps with 
roughly 6 months interval. 
3 to 4 days after treatment a radiation-induced 
wound appeared, however this disappeared completely 
within 30 to 154 days (average 65, median 53) 
depending on the area of the lesion, the body part and 
the age of the patient. Wound closing was fastest for 
small lesions of younger patients, while larger lesions 
of older patients took more time to close and the 
redness to disappear. After application if any bleeding 
was present before treatment stopped in a few days. 
Also some lesions produced a clear serum during the 
first 1-2 weeks, but it disappeared without needing any 
action. From an anatomical point of view, noses and 
cheeks healed the fastest while legs took the longest.  
All 44 patients achieved complete remission of the 
skin. The average follow-up time was 288 days (35-
1150 days, median 212 days). 34 patients had a follow-
up of more than 3 months (116-1150 days, median 304 
days). 24 patients had a follow-up of more than 6 
months (210-1150 days, median 388 days). 1 patient 
(BCC, recurrent patient after 3 surgeries) was lost to 
follow-up. The 4 patients planned to get 2 treatments 
showed complete remission after the second treatment. 
2 patients needed a second unplanned treatment for 
complete remission as the security margin showed to 
be too tight resulting in a recurrence at the border of 
the treated area. No relation between BCC and SCC 
and success / recurrence rates was observed in this 
group. No single side-effect was reported beyond the 
radiation wound during the first 30-154 days, in 
particular, no haematological toxicity was observed 
which confirms that no Rhenium-188 was incorporated. 
No medical intervention was needed to treat the local 
reaction as it healed on its own for all 44 patients in all 
treatments. No pain was present during the healing 
process. 
DISCUSSION AND CONCLUSIONS 
The treatment of skin cancer with radioisotopes has 
been performed since the 1960s. As an alternative to 
soft X-ray and electron beam irradiation, brachytherapy 
with sealed sources achieves local control rates of 90 
to 100%. Like conventional radiotherapy, its application 
is recommended as second line treatment for patients 
 
Figure 5: Left, histogram of lesion size for all 88 lesions. Right, histogram of treatment times for all 49 treatments (37 single 
treatments and 6 double treatments). 
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with lesions where surgery cannot be applied or where 
a suboptimal result is expected [2]. 
While the use of high radioactivity Iridium-192 in 
sealed form has become the standard (HDR skin 
 
          
Figure 6: Examples of lesions treated before and after the brachytherapy with Rhenium-188. 
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brachytherapy), the approach of Sedda et al. using 
non-sealed Rhenium-188 brings advantages, in 
particular in terms of personalization. 
1. Personalization: By binding the radionuclide to a 
liquid viscous matrix and applying it directly over 
the tumor, the exact shape of the lesion and a 
desired security margin can be covered. As a 
result, healthy tissue can be spared, and a 
complete conformational radiotherapy is 
performed. Furthermore the dosimetry is 
calculated on a lesion-by-lesion base and the 
treated depth can be easily controlled by varying 
the time the radionuclide stays over the tumor. 
2. Dose distribution: Rhenium-188 has a flatter 
dose distribution in depth than Iridium-192 
providing thus a more homogeneous dose to the 
tumor. On the other hand the rapid drop of dose 
after 3 mm spares underlying tissue layers. This 
is particularly of importance for mucous tissues 
like lips and genitals, but also for ears where it is 
of great importance to spare the cartilage, and 
for eye lids due to the radiation sensitive eye 
lenses. 
3. Applicability: The radioactive cream can be 
applied independently of the 3D surface and the 
anatomical position of the tumor. This advantage 
creates therapy options for anatomies, such as 
inside the ear or in the genital area, where 
sealed source brachytherapy cannot be applied. 
Since the radionuclide is applied over the skin, 
there is no risk that the patient moves relatively 
to the source. This improves the comfort for the 
patient, avoids the irradiation of healthy tissue 
and reduces the risk of not reaching the target 
dose for the tumor. 
4. Single-session: In contrast to conventional 
radiation therapy and brachytherapy with sealed 
sources, a single treatment is sufficient in most 
cases with the proposed method. A second or 
third treatments are planned only for cases with 
thick tumors or in mucous tissues. In that case, 
these applications are separated by 5-7 months. 
Such a treatment plan simplifies the logistics and 
the patient comfort, as most patients are elder 
people who benefit from not having to come for 
fractions many times a week during several 
weeks. Furthermore, there are no repositioning 
issues. 
On top of the above-mentioned advantages, the 
ones of conventional radiation therapy also apply. 
DBBR is painless, fast (in average 60 minutes) and 
leaves in most cases no scar (in some cases a faint 
discoloration of the skin is present, which can slowly 
disappear, as seen in conventional radiation therapy). 
As there is no need of anesthesia it is an ideal 
approach for elder patients. 
The current retrospective analysis shows good 
treatment results with no reported side effects. With a 
100% remission rate after two treatments and the need 
of an unplanned second treatment in only 2 cases, this 
patient group confirms the reports of Sedda et al. [6, 7] 
and the expectations from the therapy. Tumors on 
susceptible areas like ears, lips and genitals are 
recommended to be treated in several steps. The same 
applies to thick tumors or recurrent lesions in particular 
on the nose. Care needs to be taken to define 
sufficiently wide margins to avoid a second treatment. 
On the whole, DBBR is a safe alternative therapy for 
BCC and SCC practically independent of tumor shape 
and anatomy which shows good potential to become a 
valuable tool for cases where surgery cannot provide a 
satisfying solution. 
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